Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02300870 · ClinicalTrials.gov registry record
Myocardial Perfusion Echocardiography to Detect Human Heart Transplant Rejection
A clinical trial, sponsored by Brigham and Women's Hospital.
- Terminated
- Registry status
- 10
- Enrollment target
NCT02300870 is a clinical trial that was terminated before completion, run by Brigham and Women's Hospital. The registered enrollment target is 10 participants.
The verdict
NCT02300870 was terminated before completion, sponsored by Brigham and Women's Hospital.
- TERMINATED
- Registry status
- 10 participants
- Enrollment target
Study Summary
The primary objective of this proposal is to show the efficacy of contrast enhanced ultrasonography in detecting heart transplant rejection in humans. The secondary objective is to demonstrate the efficacy of this technique in generating data which allow for the assessment of short and long term outcomes.
Interventions
- DRUG Optison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2015-01 |
| Est. Completion | 2019-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02300870
The ClinicalTrials.gov registry entry for NCT02300870 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Optison is the first listed.
NCT02300870 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02300870 about?
NCT02300870 is a clinical study titled "Myocardial Perfusion Echocardiography to Detect Human Heart Transplant Rejection". The primary objective of this proposal is to show the efficacy of contrast enhanced ultrasonography in detecting heart transplant rejection in humans. The secondary objective is to demonstrate the efficacy of this technique in generating data which allow for the assessment of short and long term out...
What is the current status of trial NCT02300870?
This trial is currently terminated. The enrollment target is 10 participants. The study started on 2015-01. Estimated completion is 2019-12.
What interventions are being tested in trial NCT02300870?
The interventions under investigation include: Optison (DRUG).
Who is sponsoring clinical trial NCT02300870?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.